Материал: КР все по дерматоловенерологии 2015

3.

Olsen E. A., Carson S. C., Turney E. A. Systemic steroids with or without 2%

topical minoxidil in the treatment of alopecia areata. Arch Dermatol 1992;

128: 1467—1473.

4.

Price V. H. Treatment of hair loss. N Engl J Med 1999; 341 (13): 964—973.

5.

Sharma V. K. Pulsed administration of corticosteroids in the treatment of alo-

pecia areata. Int J Dermatol 1996; 35: 133—136.

6.

Friedli A., Labarthe M. P., Engelhardt E. et al. Pulse methylprednisolone

therapy for severe alopecia areata: an open prospective study of 45 patients.

J Am Acad Dermatol 1998; 39: 597—602.

7.

Perriard-Wolfensberger J., Pasche-Koo F., Mainetti C. et al. Pulse methyl­

prednisolone for alopecia areata. Dermatology 1993; 187: 282—285.

8.

Assouly P., Reygagne P., Jouanique C., Matard B., Marechal E., Reynert P.

et al. Intravenous pulse methylprednisolone therapy for severe alopecia areata:

An open study of 66 patient. [Article in French]. Ann Dermatol Venereol 2003;

130(3): 326—330.

9.

Kurosawa M., Nakagawa S., Mizuashi M. et al. A comparison of the efficacy,

relapse rate and side effects among three modalities of systemic corticosteroid

therapy for alopecia areata. Dermatology 2006; 212(4): 361—5.

10.

Joly P. The use of methotrexate alone or in combination with low doses of oral

corticosteroids in the treatment of alopecia totalis or universalis. J Am Acad

Dermatol 2006; 55: 632—636.

11.

Royer M., Bodemer C., Vabres P. et al. Efficacy and tolerability of methotrex-

ate in severe childhood alopecia areata. Br J Dermatol 2011; 165(2): 407—10.

12.

Fiedler-Weiss V. C. Topical minoxidil solution (1% and 5%) in the treatment

of alopecia areata. J Am Acad Dermatol 1987; 16: 745—748.

13.

Fiedler-Weiss V. C., West D. P., Buys C. M. et al. Topical minoxidil dose-re-

sponse effect in alopecia areata. Arch Dermatol 1986; 122 (2): 180—182.

14.

Tosti A., Piraccini B. M., Pazzaglia M. et al. Clobetasol propionate 0.05%

under occlusion in the treatment of alopecia totalis/universalis. J Am Acad

Dermatol 2003; 49: 96—98.

15.

Al-Gurairi F., Al-Waiz M., Sharquie K. E. Oral zinc sulphate in the treatment

of recalcitrant viral warts: Randomized placebo controlled trial. Br J Dermatol

2002; 146: 423—431.

16.

Sharquie K. E., Najim R. A., Al-Dori W. S., Al-Hayani R. K. Oral zinc sulfate

in the treatment of Behcet’s disease: a double blind cross-over study. J Derma-

tol 2006; 33: 541—546.

17.

Ead R. D. Oral zinc sulphate in alopacia areata-a double blind trial. Br J Der-

кожи

matol 1981; 104: 483—484.

18.

Kubeyinje E. P. Intralesional triamcinolone acetonide in alopecia areata

Болезни

amongst 62 Saudi Arabs. East Afr Med J 1994; 71: 674—675.

19.

cinolone acetonide by jet injector. Br J Dermatol 1973; 88: 55—59.

Abell E., Munro D. D. Intralesional treatment of alopecia areata with triam-

20.

Shapiro J., Price V. H. Hair regrowth. Therapeutic agents. Dermatol Clin

1998; 16: 341—356.

21.

Chang K. H., Rojhirunsakool S., Goldberg L. J. Treatment of severe alopecia

areata with intralesional steroid injections. J Drugs Dermatol 2009; 8: 909—912.

22.

Shapiro J., Madani S. Alopecia areata: Diagnosis and management. Int J Der-

matol 1999; 38 (Suppl 1): 19—24.

23.

Porter D., Burton J. L. A comparison of intra-lesional triamcinolone hexace-

tonide and triamcinolone acetonide in alopecia areata. Br J Dermatol 1971;

85: 272—273.

24.

Sohn K.C., Jang S., Choi D. K. et al. Effect of thioredoxin reductase 1 on

glucocorticoid receptor activity in human outer root sheath cells. Biochem

Biophys Res Commun 2007; 356: 810—815.

25.

Инструкция по применению препарата.

26.

Price V. H. Double-blind, placebo-controlled evaluation of topical minoxidil

in extensive alopecia areata. J Am Acad Dermatol 1987; 16: 730—736.

27.

Olsen E. A., Carson S. C., Turney E. A. Systemic steroids with or without 2%

topical minoxidil in the treatment of alopecia areata. Arch Dermatol 1992;

128 (11): 1467—1473.

28.

Gill K. A. Jr., Baxter D. L. Alopecia totalis. Treatment with fluocinolone ace-

tonide. Arch Dermatol 1963; 87: 384—386.

29.

Pascher F., Kurtin S., Andrade R. Assay of 0.2 percent fluocinolone acetonide

cream for alopecia areata and totalis. Efficacy and side effects including histo-

logic study of the ensuing localized acneform response. Dermatologica 1970;

141(3): 193—202.

30.

Mancuso G., Balducci A., Casadio C., Farina P., Staffa M. et al. Efficacy of

betamethasone valerate foam formulation in comparison with betamethasone

dipropionate lotion in the treatment of mild-to-moderate alopecia areata:

A multicenter, prospective, randomized, controlled, investigator-blinded trial.

Int J Dermatol 2003; 42: 572—575.

31.

Tosti A., Piraccini B. M., Pazzaglia M., Vincenzi C. Clobetasol propionate

0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am

Acad Dermatol 2003; 49: 96—98.

32.

Tosti A., Iorizzo M., Botta G. L., Milani M. Efficacy and safety of a new clo-

betasol propionate 0.05% foam in alopecia areata: a randomized, double-blind

placebo-controlled trial. J Eur Acad Dermatol Venereol 2006; 20: 1243—1247.

33.

Al-Mutairi N. 308-nm excimer laser for the treatment of alopecia areata. Der-

matol Surg 2007; 33: 1483—1487.

34.

Al-Mutairi N. 308-nm excimer laser for the treatment of alopecia areata in

гнездная

children. Pediatr Dermatol 2009; 26: 547—50.

35.

Zakaria W., Passeron T., Ostovari N., Lacour J. P., Ortonne J. P. 308-nm ex-

36.

cimer laser therapy in alopecia areata. J Am Acad Dermatol 2004; 51: 837—838.

Алопеция

Ges 2005; 3: 524—526.

Raulin C., Gundogan C., Greve B., Gebert S. Excimer laser therapy of alope-

37.

Gundogan C., Greve B., Raulin C. Treatment of alopecia areata with the

308-nm xenon chloride excimer laser: case report of two successful treatments

with the excimer laser. Lasers Surg Med 2004; 34: 86—90.

38.

Claudy A. L., Gagnaire D. PUVA treatment of alopecia areata. Arch Dermatol

1983; 119: 975—8.

39.

Lassus A., Eskelinen A., Johansson E. Treatment of alopecia areata with three

different PUVA modalities. Photodermatology 1984; 1: 141—144.

40.

Van der Schaar W. W., Sillevis Smith J. H. An evaluation of PUVA-therapy for

alopecia areata. Dermatologica 1984; 168: 250—252.

41.

Mitchell A. J., Douglass M. C. Topical photochemotherapy for alopecia area-

ta. J Am Acad Dermatol 1985; 12: 644—649.

42.

Taylor C. R., Hawk J. L. PUVA treatment of alopecia areata partialis, totalis

and universalis: audit of 10 years’ experience at St John’s Institute of Derma-

tology. Br J Dermatol 1995; 133: 914—918.

43.

Healy E., Rogers S. PUVA treatment for alopecia areata — does it work? A ret-

rospective review of 102 cases Br J Dermatol 1993; 129: 42—44.

44.

Gupta A. K., Ellis C. N., Cooper K. D. et al. Oral cyclosporine for the treat-

mtnt of alopecia areata. A clinical and immunohistochemical analysis. J AM

Acad Dermatol 1990; 22: 242—50.

45.

Fiedler-Weiss V. C. Topical minoxidil solution (1% and 5%) in the treatments

of alopecia areata.

46.

Coronel-Perez I. M., Rodriguez-Rey E. M., Camacho-Martinez F. M.

Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis.

J Eur Acad Dermatol Venerol 2010; 24: 481—5;

47.

Faghihi G., Andalib F., Asilian A. The efficacy of latanoprost in the treatment

of alopecia areata of eyelashes and eyebrows. Eur J dermatol 2009; 19: 586—7.

48.

Acikgoz G., Caliskan E., Tunca M. The effect of oral caclosporine in the treat-

ment of severe alopecia areata.

49.

De Andrade M., Jackow C. M., Dahm N., Hordinsky M., Reveille J. D., Du-

vic M. Alopecia areata in families: association with the HLA locus. J Inv Der-

matol Symp Proc 1999; 4(3): 220—223.

50.

Welsh E. A., Clark H. H., Epstein S. Z., Reveille J. D., Duvic M. Human leu-

kocyte Antigen-DQB1*03 alleles are associated with alopecia areata. J Inv

Dermatol 1994; 103 (6): 758—763.

51.

Morling N., Frentz G., Fugger L. et al. DNA polymorphism of HLA class II

genes in alopecia areata. Disease Markers 1991; 9 (1): 35—42.

52.

King L. E. Jr., McElwee K. J., Sundberg J. P. Alopecia areata. Current Direc-

кожи

tions in Autoimmunity 2008; 10: 280—312.

53.

Вольф К., Голдсмит Лоуэлл А., Кац Стивен И. и др.; пер. с англ.; общ.

ред. А. А. Кубановой. Дерматология Фицпатрика в клинической прак­

Болезни

тике. М.: Издательство Панфилова; БИНОМ. Лаборатория знаний,

2012. Т. 1. С. 833—835.